DNA topoisomerase-targeting chemotherapeutics: what's new? (Q39320242)

11 September 2017

1 reference

title

DNA topoisomerase-targeting chemotherapeutics: what's new? (English)

1 reference

Robert C A M van Waardenburg

11 September 2017

1 reference

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Selma M Cuya

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Mary-Ann Bjornsti

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

20 May 2017

1 reference

Cancer Chemotherapy and Pharmacology

11 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

1-14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json

Interaction between DNA and an Escherichia coli protein omega

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

An activity from mammalian cells that untwists superhelical DNA--a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Human mitochondrial topoisomerase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

DNA gyrase: an enzyme that introduces superhelical turns into DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

DNA gyrase action involves the introduction of transient double-strand breaks into DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

A hyper-recombination mutation in S. cerevisiae identifies a novel eukaryotic topoisomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Human TOP3: a single-copy gene encoding DNA topoisomerase III

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Cloning of cDNA encoding a novel mouse DNA topoisomerase III (Topo IIIbeta) possessing negatively supercoiled DNA relaxing activity, whose message is highly expressed in the testis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Cellular roles of dna topoisomerases: a molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Roles of eukaryotic topoisomerases in transcription, replication and genomic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

All tangled up: how cells direct, manage and exploit topoisomerase function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Human DNA topoisomerase I: relaxation, roles, and damage control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

New mechanistic and functional insights into DNA topoisomerases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Topoisomerase I inhibitors: camptothecins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Drugging topoisomerases: lessons and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Etoposide: four decades of development of a topoisomerase II inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Targeting DNA topoisomerase II in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Targeting bacterial topoisomerases: how to counter mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Mechanism of quinolone action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Tumor cell death induced by topoisomerase-targeting drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

DNA topoisomerases: structure, function, and mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

A new light on the meiotic DSB catalytic complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

A novel active DNA topoisomerase I in Leishmania donovani.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

3D molecular modeling and evolutionary study of the Trypanosoma brucei DNA Topoisomerase IB, as a new emerging pharmacological target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Thirteen-exon-motif signature for vertebrate nuclear and mitochondrial type IB topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Tumor Physiology and Charge Dynamics of Anticancer Drugs: Implications for Camptothecin-based Drug Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Subcellular localization of the camptothecin analogues, topotecan and gimatecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Dual localization of human DNA topoisomerase IIIalpha to mitochondria and nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Molecular mechanism of double Holliday junction dissolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

FANCD2 regulates BLM complex functions independently of FANCI to promote replication fork recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

The Top3β way to untangle RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

A first view of the structure of a type IA topoisomerase with bound DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

A Model for the Mechanism of Human Topoisomerase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Reconstitution of human topoisomerase I by fragment complementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

DNA topoisomerase II, genotoxicity, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Structure and mechanism of DNA topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA Cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Structure of a topoisomerase II–DNA–nucleotide complex reveals a new control mechanism for ATPase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Recent advances in understanding structure–function relationships in the type II topoisomerase mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Toprim--a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Interfacial inhibitors of protein-nucleic acid interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

21 January 2018

Interfacial inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

DNA topoisomerase-targeting antitumor drugs can be studied in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Camptothecin and taxol: from discovery to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Novel camptothecin derivatives as topoisomerase I inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Current status and perspectives in the development of camptothecins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Etoposide, topoisomerase II and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Formation of DNA adducts by formaldehyde-activated mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Catalytic topoisomerase II inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Nonlinear partial differential equations and applications: The mechanism of topoisomerase I poisoning by a camptothecin analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

Antitumour drugs impede DNA uncoiling by topoisomerase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3334-5

10.1007/S00280-017-3334-5

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28528358%20AND%20SRC:MED&resulttype=core&format=json